MoFlo to MoFlo XDP Upgrade for BSL3 Sorting

用于 BSL3 排序的 MoFlo 至 MoFlo XDP 升级

• 批准号: 8447870
• 负责人: Joseph B. Margolick
• 金额: $ 23.31万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-15 至 2014-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8447870
• 关键词: 11 year old; AIDS/HIV problem; Address; Advisory Committees; Area; Caring; Cell Separation; Contract Services; Core Facility; Data; Disease; Environment; Future; Gene Expression Regulation; Generations; HIV; HIV Infections; Hepatitis Viruses; Housing; Human; Immune; Infection; Investigation; Laboratories; Life Expectancy; Malignant Neoplasms; Manufacturer Name; Neurodegenerative Disorders; Organism; Pathogenesis; Prevention; Principal Investigator; Procedures; Public Health Schools; Publications; Research; Research Personnel; Research Project Grants; Role; Sampling; Sorting - Cell Movement; Specimen; Speed; Stem cells; Time; Training; Universities; cost effective; experience; human disease; in vivo; instrument; nervous system disorder; operation; pathogen; success

DESCRIPTION (provided by applicant): This application addresses the ongoing need at Johns Hopkins University (JHU) for high-speed cell sorting of specimens infected with organisms which are biohazardous to humans. It requests support to upgrade a Beckman Coulter MoFlo Legacy flow cytometer, housed in a biosafety level 3 (BSL3) laboratory in the Johns Hopkins Bloomberg School of Public Health, to the functional equivalent of a MoFlo XDP flow cytometer. The MoFlo Legacy cytometer in question is more than 11 years old, is tenuous as a critical instrument to support a large number of research projects that depend on it (specifically projects in the areas of HIV/AIDS, cancer, neurodegenerative diseases, and other diseases of human cells where sorting in a protected environment is appropriate), and will no longer be supported by the manufacturer as of late 2013. As most cell sorting facilities at JHU refer to us the sorting of human samples that may contain agents such as hepatitis viruses or other pathogens, and our laboratory is the main biosafety level 3 (BSL3) cell sorting facility at JHU, a reliable and adequately sophisticated sorter is critical for the continued success of this facility, which has contributed data to at least 70 publications, including important advances in understanding and care of HIV infection, since the acquisition of the current cytometer. The laboratory team is well experienced in management of a BSL3 core facility, with the principal investigator of this application having directed this facility since 1989. With the current MoFlo cytometer now reaching its life expectancy, upgrading and modernizing it are a) needed to sustain and expand the current scale of research, and b) much more cost-effective for this purpose than purchasing a new sorting cytometer. Among the HIV-related research areas that depend on this facility are understanding the generation and possible mechanisms of eradication of HIV reservoirs in vivo, immune pathogenesis of HIV infection, and pathogenesis of HIV-related infections. Other areas of human investigation include pathogenesis of neurological disease, role of stem cells in cancer and other diseases, and aspects of gene regulation in many human diseases. Specific research projects of 5 major investigators and numerous other users of the core that would benefit from continued availability and reliability of this facility are described, as are the specific features of the MoFlo upgrade that justify its acquisition. Many other projects would also use the new sorter over its lifetime. Procedures and plans for sustaining the cell sorting facility's ability to support HIV and human research at JHU for the future are described, as are financial plans for operation of the facility including institutional support comprised of covering the service contract for the upgraded cytometer and any financial shortfalls that may develop. The facility will be operated by an experienced full-time cytometer operator and a new operator to be trained and supervised by the facility director, with oversight by an internal advisory committee. With the requested upgrade, the facility will continue to make unique contributions to the treatment, management, and prevention of HIV infection and other human diseases for many years.

描述（由申请人提供）：本申请解决了约翰霍普金斯大学（JHU）对感染对人类具有生物危害性的微生物的标本进行高速细胞分选的持续需求。它请求提供支持，将约翰霍普金斯彭博公共卫生学院生物安全3级实验室中的Beckman Coulter MoFlo Legacy流式细胞仪升级为功能等同于MoFlo XDP流式细胞仪。问题中的MoFlo Legacy血细胞计数器已有11年多的历史，作为支持大量依赖于它的研究项目（特别是艾滋病毒/艾滋病、癌症、神经退行性疾病和其他人类细胞疾病领域的项目，在受保护的环境中进行分选是合适的）的关键仪器是脆弱的，并且从2013年底起将不再得到制造商的支持。由于JHU的大多数细胞分选设施都是指我们对可能含有肝炎病毒或其他病原体等病原体的人体样本进行分选，而我们的实验室是JHU的主要生物安全3级（BSL 3）细胞分选设施，因此可靠且足够复杂的分选机对于该设施的持续成功至关重要，该设施已为至少70篇出版物提供了数据，包括自购置现有细胞仪以来在了解和护理艾滋病毒感染方面取得的重要进展。实验室团队在BSL 3核心设施的管理方面经验丰富，本申请的主要研究者自1989年以来一直指导该设施。随着当前MoFlo细胞仪达到预期寿命，需要对其进行升级和现代化，以维持和扩大当前的研究规模，以及B）为此目的比购买新的分选细胞仪更具成本效益。依赖于该设施的HIV相关研究领域包括了解体内HIV宿主的产生和可能的根除机制、HIV感染的免疫发病机制以及HIV相关感染的发病机制。人类研究的其他领域包括神经系统疾病的发病机制，干细胞在癌症和其他疾病中的作用，以及许多人类疾病中的基因调控方面。具体的研究项目的5个主要调查员和许多其他用户的核心，将受益于持续可用性和可靠性的这一设施，是MoFlo升级的具体功能，证明其收购。许多其他项目也将在其生命周期内使用新的分拣机。维持细胞分选设施的能力，以支持艾滋病毒和人类研究在JHU的未来的程序和计划进行了说明，是该设施的运作，包括机构支持的财务计划，包括覆盖升级的细胞计数器的服务合同和任何可能发展的财政短缺。该设施将由一名经验丰富的全职细胞仪操作员和一名新操作员操作，新操作员将接受设施主任的培训和监督，并由一个内部咨询委员会监督。随着所要求的升级，该设施将继续多年来为治疗、管理和预防艾滋病毒感染和其他人类疾病作出独特贡献。